MicroRNA 122 as adiagnostic biomarker for hepatitis C- related hepatocellular carcinoma
El-Sayed Shiha, G., Elbaz El agroudy, O., mohamad Seif, S., Hakim Elmenshawy, H., Abd El-Magid, I. (2019). MicroRNA 122 as adiagnostic biomarker for hepatitis C- related hepatocellular carcinoma. EKB Journal Management System, 4.1(1), 35-43. doi: 10.21608/mjvh.2019.59524
Gamal El-Sayed Shiha; Osama Elbaz El agroudy; Seham mohamad Seif; Hazem Hakim Elmenshawy; Ibrahim Abd El-Magid. "MicroRNA 122 as adiagnostic biomarker for hepatitis C- related hepatocellular carcinoma". EKB Journal Management System, 4.1, 1, 2019, 35-43. doi: 10.21608/mjvh.2019.59524
El-Sayed Shiha, G., Elbaz El agroudy, O., mohamad Seif, S., Hakim Elmenshawy, H., Abd El-Magid, I. (2019). 'MicroRNA 122 as adiagnostic biomarker for hepatitis C- related hepatocellular carcinoma', EKB Journal Management System, 4.1(1), pp. 35-43. doi: 10.21608/mjvh.2019.59524
El-Sayed Shiha, G., Elbaz El agroudy, O., mohamad Seif, S., Hakim Elmenshawy, H., Abd El-Magid, I. MicroRNA 122 as adiagnostic biomarker for hepatitis C- related hepatocellular carcinoma. EKB Journal Management System, 2019; 4.1(1): 35-43. doi: 10.21608/mjvh.2019.59524

MicroRNA 122 as adiagnostic biomarker for hepatitis C- related hepatocellular carcinoma

Medical Journal of Viral Hepatitis
Article 5, Volume 4.1, Issue 1, November 2019, Page 35-43  XML PDF (168.41 K)
Document Type: Original article
DOI: 10.21608/mjvh.2019.59524
View on SCiNiTO View on SCiNiTO
Authors
Gamal El-Sayed Shiha1; Osama Elbaz El agroudy2; Seham mohamad Seif3; Hazem Hakim Elmenshawy3; Ibrahim Abd El-Magid3
1Internal Medicine dept., Mansoura Univ.; Egyptian Liver Research Institute and Hospital (ELRIH), Sherbin, El-Mansoura, Egypt
2Clinical Pathology dept., Mansoura Univ., Mansoura, Egypt
3Internal Medicine dept., Mansoura Univ., Egypt
Abstract
Aim: To explore the potential usefulness of serum microRNA
(miR-122) as non-invasive diagnostic marker for hepatitis C virus
(HCV)-related hepatocellular carcinoma (HCC). Methods: The
study has been conducted on 100 participants and were divided into 4
equal groups: Group I; Twenty five normal, healthy individuals. age
and gender-matched healthy volunteers (control group). Group II;
Twenty five chronic HCV patients without cirrhosis. Group III;
Twenty five HCV related cirrhosis without HCC. Group IV; Twenty
five HCV-related HCC (proved radiologically by abdominal ultrasonography
(US) & Triphasic abdominal computed tomography (CT). All
participants underwent full clinical assessment and laboratory
investigations in addition to the evaluation of the level of serum miR-
122 by RT-PCR. Results: microRNA-122 displayed significant fold
increase in expression level in chronic hepatitis group (9.85), and less
significant fold increase in cirrhosis group (3.73) and significant
fold increase in expression level in HCC group (7.46). Comparing
serum miR-122 expression level between different studied groups
displayed that, No significant fold change in miR-122 expression
was found between different groups and that miRNA122 had no
significant up-regulation in HCC patients in comparison to non-HCC
patients (Hepatitis and Cirrhosis); (P value = 0.682). Specificity &
sensitivity was 94% & 16% respectively, with AUROC (0.529).
Conclusion: miR-122 could not be used as a biomarker for early
detection of HCC in HCV related cirrhosis.
Keywords
miR-122; Hepatocellular carcinoma; chronic hepatitis C and cirrhosis
Statistics
Article View: 453
PDF Download: 486